A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Stable Subjects With Mixed Dyslipidemia

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Stable Subjects With Mixed Dyslipidemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Icosabutate (Primary)
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Pronova BioPharma
  • Most Recent Events

    • 06 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Nov 2013 New trial record
    • 01 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top